Article Figures & Data
Figures
- Figure 1.
Participant enrollment and randomization to the study. Arm A (left column) allocated to oral bicarbonate and arm B (right colum) allocated to standard therapy.
- Figure 2.
(A) Plasma HCO3− levels during the study period. Squares and bars denote means and SD. (B) Urinary sodium (Na) excretion per day. Squares and bars denote means and SD. (C) BP control during the study period. Squares and bars denote means and SD. (D) Urinary total protein excretion per day during the study period. Squares and bars denote means and SD. (E) Rate of decline of CrCl. Squares and bars denote means and SD.
- Figure 3.
Kaplan-Meier analysis to assess the probability of reaching ESRD for the two groups.
- Figure 4.
(A) Dietary protein intake on 4-d patient dietary records. Data are means and SD. (B) nPNA during the study period. Data are means and SD. (C) MAMC measurements during the study period. Data are means and SD. (D) Plasma albumin levels in the control and bicarbonate groups during the study period. Data are means and SD. (E) Serum potassium levels in the control and bicarbonate groups during the study period. Data are means and SD.
Tables
Variable Control Bicarbonate Demographic age (yr; mean ± SE) 54.77 ± 2.34 54.78 ± 2.56 male (%) 51 52 white (%) 52 52 black/Asian (%) 48 48 Diagnosis (%) diabetes 36 37 hypertension 26 29 CRF unknown 14 10 glomerulonephritis 13 10 obstructive uropathy 4 1 other 7 12 Medications (%) loop diuretics 67 70 moxonodine 15 17 α blockers 57 59 β blockers 17 19 calcium channel blockers 48 50 ACEIs/ARBs 48 50 allopurinol 3 0 -
↵aCRF, chronic renal failure.
-
Variable Control Bicarbonate P Weight (kg) 74.9 ± 11.5 76.6 ± 21.1 0.84 Systolic BP (mmHg) 123.7 ± 1.2 124.0 ± 1.3 0.84 Diastolic BP (mmHg) 75.4 ± 1.9 76.1 ± 1.5 0.91 MAMC (cm) 24.8 ± 2.4 24.6 ± 2.9 0.81 Albumin (g/L) 35.1 ± 0.8 34.7 ± 0.5 0.76 Bicarbonate (mmol/L) 19.9 ± 1.5 19.8 ± 2.2 0.66 CrCl (ml/min per 1.73 m2) 20.70 ± 5.55 20.12 ± 6.47 0.60 Urinary Na (mmol/L) 140.1 ± 4.4 140.0 ± 7.9 0.96 Urinary protein (g/24 h) 1.8 ± 0.2 1.7 ± 0.8 0.84 -
↵aData are means ± SE.
-
Adverse Events Control (% of Patients) Bicarbonate (% of Patients) P Hospitalization for CHF 0 0 N/A Worsening hypertension requiring increase in therapy 48 61 0.17 Worsening edema requiring increase in loop diuretics 30 39 0.5 Bad taste requiring switch to powder form of sodium bicarbonate N/A 6.5 N/A -
↵aCHF, congestive heart failure.
-
Bicarbonate Supplementation Slows Progression of CKD and Improves Nutritional Status
Files in this Data Supplement:
In this issue
Bicarbonate Supplementation Slows Progression of CKD and Improves Nutritional Status
Jump to section
More in this TOC Section
Cited By...
- Fatigue in CKD: Epidemiology, Pathophysiology, and Treatment
- The Continuum of Acid Stress
- Assessment of the Potential for Veverimer Drug-Drug Interactions
- Mechanism of Action of Veverimer: A Novel, Orally Administered, Nonabsorbed, Counterion-Free, Hydrochloric Acid Binder under Development for the Treatment of Metabolic Acidosis in Chronic Kidney Disease
- Low Serum Bicarbonate and CKD Progression in Children
- Chronic kidney disease in adults: assessment and management
- Mechanisms of Metabolic Acidosis-Induced Kidney Injury in Chronic Kidney Disease
- Sodium Bicarbonate Supplementation and Urinary TGF-{beta}1 in Nonacidotic Diabetic Kidney Disease: A Randomized, Controlled Trial
- A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial
- Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis
- Effects of Treatment of Metabolic Acidosis in CKD: A Systematic Review and Meta-Analysis
- Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease
- Effect of Treatment of Metabolic Acidosis on Vascular Endothelial Function in Patients with CKD: A Pilot Randomized Cross-Over Study
- Metabolic Acidosis and Cardiovascular Disease Risk in CKD
- Buffering chronic kidney disease with sodium bicarbonate
- Adenylyl cyclase 6 in acid-base balance - adding complexity
- Mechanism of Hyperkalemia-Induced Metabolic Acidosis
- The Role of Bicarbonate in Cognition: Acidosis May Be Corrosive to the Brain
- NBCe1-A Regulates Proximal Tubule Ammonia Metabolism under Basal Conditions and in Response to Metabolic Acidosis
- Association between Urine Ammonium and Urine TGF-{beta}1 in CKD
- Metabolic Acidosis and Subclinical Metabolic Acidosis in CKD
- Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD
- New Frontiers in Treating Uremic Metabolic Acidosis
- Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders
- Association Between Acidosis Soon After Reperfusion and Contrast-Induced Nephropathy in Patients With a First-Time ST-Segment Elevation Myocardial Infarction
- Urine Ammonium Predicts Clinical Outcomes in Hypertensive Kidney Disease
- Acidosis and Kidney Allograft Survival
- Metabolic Acidosis and Long-Term Clinical Outcomes in Kidney Transplant Recipients
- Red Meat Intake and Risk of ESRD
- Rate of Decline of Residual Kidney Function Before and After the Start of Peritoneal Dialysis
- Bicarbonate Concentration, Acid-Base Status, and Mortality in the Health, Aging, and Body Composition Study
- Pathophysiologic Changes in Extracellular pH Modulate Parathyroid Calcium-Sensing Receptor Activity and Secretion via a Histidine-Independent Mechanism
- Lower urinary pH is useful for predicting renovascular disorder onset in patients with diabetes
- Urea and Ammonia Metabolism and the Control of Renal Nitrogen Excretion
- High Dietary Acid Load Predicts ESRD among Adults with CKD
- Persistent High Serum Bicarbonate and the Risk of Heart Failure in Patients With Chronic Kidney Disease (CKD): A Report From the Chronic Renal Insufficiency Cohort (CRIC) Study
- Current Status of Bicarbonate in CKD
- Acid-Base Balance and Physical Function
- Autophagic Clearance of Mitochondria in the Kidney Copes with Metabolic Acidosis
- The Role of the Renal Ammonia Transporter Rhcg in Metabolic Responses to Dietary Protein
- A Within-Patient Analysis for Time-Varying Risk Factors of CKD Progression
- Dietary Acid, Age, and Serum Bicarbonate Levels among Adults in the United States
- A Patient with CKD and Poor Nutritional Status
- Mediterranean Diet, Kidney Function, and Mortality in Men with CKD
- Management of protein-energy wasting in non-dialysis-dependent chronic kidney disease: reconciling low protein intake with nutritional therapy1,3
- Effects of Oral Sodium Bicarbonate in Patients with CKD
- The Role of Bicarbonate in CKD: Evidence Bulks Up
- A Comparison of Treating Metabolic Acidosis in CKD Stage 4 Hypertensive Kidney Disease with Fruits and Vegetables or Sodium Bicarbonate
- Treatment of Acidosis in CKD
- Frailty and Protein-Energy Wasting in Elderly Patients with End Stage Kidney Disease
- Dialysis Modality and Correction of Uremic Metabolic Acidosis: Relationship with All-Cause and Cause-Specific Mortality
- Basically, Dialysis Is Not Good Enough
- Dietary Acid Load and Metabolic Acidosis in Renal Transplant Recipients
- Correction of Metabolic Acidosis with Potassium Citrate in Renal Transplant Patients and its Effect on Bone Quality
- Molecular Mechanisms of Acid-Base Sensing by the Kidney